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It has been a great honor to have served as the
22nd President of the Midwestern Vascular Surgical
Society (MWVSS), and I will forever be grateful for
the friendship and support extended to me by all my
friends.
As I reflected over the last 6 months about a
topic for a presidential address, reviewing previous
speeches and calling on friends in the field of vascu-
lar surgery to elicit their ideas, I found a common
thread regarding the merging of new technology
and future approaches to vascular disease. We live in
an era of unprecedented biomedical and technolog-
ical advances, tempered by dramatic reductions in
reimbursement by government and third-party pay-
ers. Having read historical, philosophical, scientific,
and inspirational addresses, I concluded that a per-
sonal perspective on the challenges and opportuni-
ties that our specialty faces at the end of the millen-
nium would be an appropriate selection.
The last 50 years have brought amazing advances
in health care, such as the polio vaccine, computer-
ized imaging, birth control pills, in vitro fertiliza-
tion, solid organ transplants, medical health insur-
ance plans for the elderly population, and, most
recently, the decoding of the human genome.
Despite the privilege of being part of an amazing
period of discoveries and technological advances,
our specialty, vascular surgery, is faced with many
challenges. Some of these challenges are common to
the medical profession in general, and others are
specific to our specialty.
In choosing the title for this address, I have used
the word challenge advisedly. In its several defini-
tions, this word embodies the difficulties and goals
with which we are faced as the next century unfolds.
The first definition relates to “a call to explain or jus-
tify.” Who are we? And, growing out of that query,
Where are we going? First and foremost, we are
physicians of the vascular system, students of its biol-
ogy, researchers into its secrets, and, despite debate
to the contrary, we are proudly involved in both the
medical and surgical treatment of vascular diseases.
To meet the difficulties and attain the goals ahead of
us, we are obliged to take stock of where we are and
from where we came.
HISTORICAL PERSPECTIVE
The MWVSS was born on October 12, 1976, at
the Conrad Hilton in this majestic city (Chicago). It
was the brainchild of Drs Emerick Szilagyi, John
Bergan, and James Stanley, our first three presidents.
Eight of the 12 surgeons in the committee who
called for the first organizational meeting—held in
Buffalo, New York in March of 1977—became pres-
idents of this society. In this founding meeting, Dr
Szilagyi wisely pointed out that the primary purpose
of the society should be educational, and that scien-
tific fellowships would be the most valuable aspect of
membership. The scientific program in this meeting
proudly represents that purpose. The MWVSS’s
objectives are (1) the advancement of the science
and art of peripheral vascular surgery and (2) the
maintenance of high standards in its practice. As we
face multiple challenges in vascular surgery, we must
remain fully committed to these objectives to safe-
guard our highest goal: the best possible treatment
for our patients with vascular diseases.
Presidential address: Challenge to our
specialty: The vascular surgeon in the year
2010
Gregorio A. Sicard, MD, St Louis, Mo
845
From the Department of Surgery, Vascular Section, Washington
University School of Medicine.
Competition of interest: nil.
Presented at the Twenty-third Annual Meeting of the Midwestern
Vascular Surgical Society, Chicago, Ill, Sep 23-25, 1999.
Reprint requests: Gregorio A. Sicard, MD, Washington
University Medical Center, One Barnes Hospital Plaza, Suite
5103, St Louis, MO 63110.
J Vasc Surg 2000;31:845-50.
Copyright © 2000 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/2000/$12.00 + 0 24/6/106482
doi:10.1067/mva.2000.106482 
CLINICAL RESEARCH STUDIES
From the Midwestern Vascular Surgical Society
The MWVSS has been blessed with dedicated
leaders who have protected and advanced our spe-
cialty. Leaders in vascular surgery, such as Drs Edwin
J. Wiley, Jesse Thompson, F. William Blaisdell,
James DeWeese, and Allan Callow, have shaped the
terrain in which vascular surgery has been built. In
1981, their leadership and tenacity led to the
approval of guidelines for vascular surgery training
programs by the American Board of Surgery, the
American Board of Thoracic Surgery, and their 
corresponding Resident Review Committees. In
November 1982, the American Board of Medical
Specialties approved the development of qualifying,
and later, certifying examinations in vascular surgery.
In 1984, the Resident Review Committee approved
the first Accreditation Council for Graduate Medical
Education training program in vascular surgery. Ever
since, vascular surgery has been an identifiable spe-
cialty that has matured under the guidance of vari-
ous outstanding midwestern practitioners and teach-
ers, including Drs James Stanley, John Bergan,
James Yao, Norman Hertzer, William Baker, and
Jonathan Towne. These men have “graced” the
presidency of the MWVSS and, from time to time,
our national organizations as well. For their many
and varied contributions, we in the field of vascular
surgery owe them a tremendous debt of gratitude.
As we enter the new millennium, the future of
our specialty rests on the shoulders of a third gener-
ation of leaders in vascular surgery. The goals of these
new leaders include the enhancement of our identity
either as a vascular sub-board within the American
Board of Surgery, or as a separate American Board of
Vascular Surgery, should that be the direction most
suitable to the challenges ahead.
Let us focus briefly on the development of mod-
ern abdominal aortic aneurysm (AAA) therapy as an
example of a clinical entity that exemplifies where we
came from and where we are now. Without this
understanding, we will be disadvantaged as we con-
sider our future. 
By touching the untouchable, Rudolph Matas1
opened the door for more modern approaches to
follow in the treatment of AAAs in 1923. Over the
last 50 years, the effective treatment of AAAs and
the understanding of their pathobiology has been
dramatic (Fig 1). The feasibility of graft repair for
the AAA was first demonstrated by Dr Charles
Dubost in 1951.2 This was shortly followed by the
development and clinical application of prosthetic
vascular grafts pioneered by Voorhees and his col-
leagues.3 Drs Michael DeBakey4 and Stanley
Crawford5 led the effort toward wider and more
successful applications of elective graft repair of
AAAs in the 1960s. Our first president, Dr Emerick
Szilagyi, established the efficacy of elective graft
repair in preventing deaths from aneurysm rupture.6
The safety of elective repair was broadened through
the 1970s by many investigators and was highlight-
ed in Dr John Mannick’s 1980 report of 110 con-
secutive elective procedures without an operative
mortality.7
Basic research on the pathogenesis of AAAs was
stimulated in 1980 by Dr Busuttil’s hypothesis that
activation of elastases and collagenases may con-
tribute to aortic wall degeneration.8 In 1984, Drs
Tilson and Seashore9 convincingly demonstrated that
there is a genetic component to AAA disease. In the
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Fig 1. Clinical and research developments in the treatment of AAAs. 
meantime, Dr Dobrin’s studies provided experimen-
tal support for the notion that elastin and collagen
degradation are critical in aneurysm disease.10 In
1991, Drs Powell and Vine11 first suggested that
matrix metalloproteinases are involved in this process.
Although the reported operative mortality for
elective AAA repair was frequently quoted as being
less than 4% by the end of the 1980s, Dr Juan
Parodi,12 in September of 1990, revolutionized the
treatment of infrarenal AAA when he performed the
first successful endoluminal aneurysm repair.
Parodi’s landmark contribution, 48 years after
Dubost’s homograft repair, opened the door to
major reductions in the risks (Fig 2) associated with
invasive treatment of infrarenal AAAs.
During the latter half of this decade, several clin-
ical trials examined the potential benefits of surgical
repair of small AAAs.13,14 Corollary questions from
these studies address issues of cost-effectiveness and
efficacy of potential pharmacologic strategies.15 A
pilot study of small AAAs evaluating the pharmaco-
logic inhibition of metalloproteinases is currently
underway, led by five prominent vascular divisions in
the Midwest (Loyola Medical Center, Mayo Clinic,
University of Nebraska, Northwestern University,
and Washington University in St Louis). Three other
nonmidwestern vascular divisions (University of
Arizona in Tucson, University of Washington in
Seattle, and Cornell Medical Center) have also
joined this important pilot trial. We in the MWVSS
are in the groundbreaking role in this area. In recog-
nition of this contribution and its seminal impor-
tance, the National Heart, Lung, and Blood
Institute (NHLBI) and the National Institutes of
Health (NIH) published a Request for Application
(RFA) earlier this year. The main goal of the RFA is
to advance the understanding of the pathobiology of
AAAs at the molecular level. The mechanism of sup-
port of this RFA will be through collaborative RO1
grants combining basic research and clinical studies.
The NHLBI will fund six to eight RO1 grants
beginning October 1, 1999. This program will
include an annual meeting of investigators and other
clinician-scientists interested in aneurysmal disease.
So, when we are collectively asked Who are you? and
Where have you been? we can, as an example,
proudly point to the evolving treatment of AAAs.
The second meaning of challenge is “difficulty in
a job or undertaking that is stimulating to one
engaged in it.” Analysis of our future establishes
both the difficulties and the rewards that lie ahead.
From questions of competition from other special-
ties and diminishing reimbursement to issues of the
design and funding of basic research, funding of
training programs, outcome data guidelines, and the
explosive growth of novel technologies in search of
applications, our specialty is truly challenged to
adapt to a new terrain in the next decade.
DIMINISHING REIMBURSEMENT
Reimbursement has been affected by many fac-
tors, including the sweeping encroachment of man-
aged care and the draconian reductions in HMO and
Medicare reimbursement. In fact, there has been a
negative impact on vascular surgery reimbursement
since the introduction of the Resource-Based
Relative-Value Scale (RBRVS) implemented in 1992
by the Health Care Financing Administration
(HCFA). Underrepresentation of vascular surgery in
the Harvard/Hsiao study, on which the RBRVS was
based, led to underpayment for vascular surgery care.
Spearheaded by Dr Norman Hertzer, the Joint
Council of the Society for Vascular Surgery and the
North American Chapter of the International Society
for Cardiovascular Surgery led a successful effort,
resulting in a positive payment adjustment in eleven
of the most common vascular surgery procedure
codes.16 While HCFA increased the evaluation and
management codes by 15% to 20%, it decreased the
work component reimbursement by 8.3% to main-
tain budget neutrality. As a result, 200 vascular codes
were kept at the low 1992 reimbursement level. A
Resource-Based Practice Expense recommendation
developed by HCFA projected an 11% payment
reduction for vascular surgical procedures. The
Government Relations Committee (GRC) of the
Joint Vascular Societies has been very active in
reviewing the codes affecting vascular surgery and
challenging HCFA to correct this trend. At the same
time, the GRC is pushing for the creation of new
CPT codes for endovascular aneurysm repair among
other new procedures.
In the practice expense portion, which compris-
es one of the three components of physician services
reimbursement, significant reductions have been
proposed by HCFA. In response, the GRC of the
Joint Council stepped up to the plate with a written
survey based on vascular surgical practices. Using
the same questions as the AMA survey, the GRC of
the Joint Council found that the Vascular Surgery
Expense Value was 34% greater ($85.60) than
HCFA’s original figure. Inadequate vascular sam-
pling, along with faulty combining practice expenses
with cardiothoracic surgery, led to an erroneously
low practice expense allocation. Despite its willing-
ness to separate vascular surgery practice expenses
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from cardiothoracic surgery, HCFA has agreed to
only a 5.8% ($67.50) improvement in physician
expense RVUS. As a society, we need to actively sup-
port the important efforts of the GRC of the Joint
Council. The accumulation of reductions in reim-
bursement will have an impact on the future stabili-
ty of our specialty by affecting recruitment of facul-
ty to academic institutions and training candidates.
Our persistent commitment to the goal of fair reim-
bursement should improve our outlook on this dif-
ficult challenge.
COMPETITION FROM OTHER 
SPECIALTIES
Over the last 15 years, the endoluminal treat-
ment of vascular disease has rapidly evolved. Balloon
angioplasty and stenting of coronary, iliac, and renal
artery and even cerebral arterial disease is common
practice. In spite of reports of a few visionary vascu-
lar surgeons regarding the benefits of this minimally
invasive approach, it has fallen with few exceptions
into the territory of interventional radiologists and
cardiologists. The successful endoluminal repair of
an AAA by Dr Juan C. Parodi in September 1990,
along with the continued success of iliac and renal
angioplasty and stenting, has raised additional con-
cerns among vascular surgeons. Recent interest by
interventional cardiologists in the treatment of
peripheral vascular disease has underscored the
importance of adding minimally invasive techniques
to the armamentarium of the vascular surgeon.17
The role that vascular surgeons and interven-
tionalists (in radiology and cardiology) will play in
the treatment of vascular disease in the next decade
remains to be defined. Despite the uncertain status
of what the distribution of endoluminal treatment
will be among the three competing specialties, it is
clear that vascular surgeons must be active partici-
pants. The resolution of “turf battles” is critical to
this debate because such occurrences are counter-
productive, tend to increase health care costs, and,
most significantly, affect patient care. One should
not forget that patient endoluminal procedures
involve the implicit “clearance” by a vascular sur-
geon for the more invasive open procedure, should
it become necessary. A strong call for outcome data
should speak directly to this concern.
Some vascular surgeons, both in academic and
private practice, have achieved the endoluminal skills
required to successfully treat patients with vascular
disease without establishing collaborative agree-
ments with other specialties. Others are forced to
obtain the necessary endoluminal skills by training in
centers in which collaborative multidisciplinary
agreements are being tested. One of the main chal-
lenges facing vascular surgeons is the need to estab-
lish an efficient strategy that will allow us to train
practicing vascular surgeons who desire adding
endoluminal skills to their treatment options. A few
midwestern academic vascular divisions have taken a
leadership role in this effort. A prompt and aggres-
sive national strategy by endoluminally skilled
groups is needed to provide the practicing vascular
surgeons the skills required to maximize care for the
vascular patient.
The vascular program at Washington University
Medical School/Barnes-Jewish Hospital has had a
successful joint venture with Interventional
Radiology for the past 2 years.18 Because of tradi-
tional department structures, this multidisciplinary
approach has met with considerable resistance in
many institutions. We have trained four fellows who
have achieved the necessary experience to fulfill the
guidelines regarding the number of catheterizations
and interventions reported by the Endovascular
Committee of the Vascular Societies.19 We have
found this approach to be beneficial for our training
program and hope to be a local and regional
JOURNAL OF VASCULAR SURGERY
848 Sicard May 2000
Estimated specialty manpower with endoluminal
skills in the midwestern region
Midwestern geographical area
No. of No. of No. of
interventional interventional vascular
cardiologists* radiologists† surgeons‡
Illinois 340 109 60
Indiana 137 69 23
Iowa 61 19 13
Kansas 51 19 8
Michigan 245 93 67
Minnesota 130 35 13
Missouri 155 61 28
Nebraska 43 36 7
North Dakota 15 7 3
Ohio 320 104 74
Oklahoma 66 17 1
South Dakota 15 10 1
Wisconsin 108 54 33
Total 1686 633 331
*Based on the proportion (34%) of interventional and invasive
cardiologists of the total midwestern cardiology pool.
†Data from the membership roster of the Society of
Cardiovascular and Interventional Radiology.
‡Data from the membership roster of the MWVSS.
resource for the training of practicing vascular sur-
geons.
Although vascular surgeons seem to be at a
numerical disadvantage in the endoluminal arena,
burgeoning volume will make this a “growth” area
for years to come (Table). Our aging population,
along with forfeiture of currently held volume by
general and cardiothoracic surgeons who do not
wish to commit to endoluminal training, will further
bolster vascular surgery’s position. The average year-
ly volume of major arterial procedures of non-HMO
Medicare patients (carotid endarterectomy, lower
extremity revascularization, AAA repair) per surgeon
is 62 by vascular surgeons, 24 by cardiothoracic sur-
geons, 17 by general surgeons, and 10 by neurosur-
geons (J. Cronenwett, oral communication, Sep
1999). In the Thoracic Surgery Workforce Report of
1995,20 based on 1992 and 1993 data collected by
a mailed questionnaire, it was found that 1455
(54%) of 2677 of practicing thoracic surgeons par-
ticipating in the survey perform a mean number of
49 vascular procedures yearly.
Any challenge offers an opportunity. Vascular
surgeons are in a unique position to expand their
therapeutic armamentarium by learning catheter-
guided skills that will provide a wider range of alter-
natives for patients with vascular disease. The oppor-
tunities available to our specialty were well stated by
Dr Richard Kempczinski21:
The key to survival in these challenging times appears
to be flexibility. Rather than ceding nonsurgical care to
vascular medicine and catheter-guided therapy to inter-
ventional radiologists or cardiologists, we should jealously
guard the broad range of skills that have made vascular
surgeons unique among tertiary care specialists and
aggressively embrace new technology that would allow us
to improve patient care and/or decrease morbidity.
FUNDING OF RESEARCH AND TRAINING
PROGRAMS
Concerns about decreased government-funded
research during the last decade has been tempered
by a recent 15% increase in NIH disbursement.
Despite this increase, discrepancies exist in funding
of clinical research, as opposed to basic science sup-
port.23 Academic vascular programs must encourage
young surgeons to develop research activities in vas-
cular diseases. We must compete with our medical
colleagues to decipher the mysteries of vascular dis-
ease. A strong commitment to protected time for
research activity, along with direct departmental
funding, can be extremely productive (Fig 3).
Multiple funding sources are currently available to
our young vascular surgeons and investigators. In the
last decade, the Lifeline Foundation has been a major
source of start-up funding for many young investiga-
tors. With the continued support of industry, vascular
surgeons, and various philanthropic sources, the fund-
ing scope of the Lifeline Foundation has increased
significantly. The Lifeline Foundation and the
NHLBI jointly sponsored Mentored Clinical Scientist
Development Awards and the Clinical Research
Award, which will begin funding July 1, 2000. We
can proudly point out the strong commitment to
basic and clinical research by the MWVSS and other
regional societies that have made it possible for the
Lifeline Foundation to develop new research pro-
grams. The continued support to the Lifeline
Foundation by all vascular surgeons remains critical
to the development of young investigators. In this era
of dramatic reductions in Medicare direct payment for
residency training, the strong support of the vascular
community helps secure our future as students and
physicians of vascular biology pathology.
So now we have examined from where we came
and on which path we are traveling. But what of
2010? I see a stronger specialty in collaborating with
radiographic and cardiologic peers to provide state-
of-the-art minimally invasive and invasive proce-
dures. 
We in the specialty must occupy a central posi-
tion in this arrangement according to our ability to
address the needs for open procedures as such needs
arise. Above all, we will remain a repository where
the goals of superb patient care and unparalleled
physician training reside. As Robert Pinski, US Poet
Laureate, stated in the 1999 Stanford University
commencement address:
Honor our predecessors and care for the young. The
most important thing about you will not be the prizes you
win or your accomplishments. Thank those predecessors
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Fig 2. Publications in basic research and open surgical and
endoluminal treatment of aneurysms.
who preserved and perfected those skills for you by main-
taining them for those to follow you. I charge you not to
break the chain.22a
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Fig 3. Funding sources of two young midwestern academic vascular surgeons.
